Making Serendipitous Discoveries Accessible to Everyone

During this time, we encountered significant challenges in early drug discovery: The time-consuming and costly hit identification via high-throughput screening and the poor hit quality of DNA-encoded library technology which leads to costly and time-consuming hit follow-up. These are tremendous obstacles, especially for small companies, which are the main drivers of innovation in drug discovery today. Finding a way out was our inspiration to design a new solution. We have developed an entirely new approach to the fastest and most cost-efficient hit identification that allows for serendipity and delivers high-quality hits. Serengen was founded in 2019 to make serendipitous discoveries accessible to everyone!